Home Page

Our Trust is proud to be taking part in the Cancer Vaccine Launch Pad (CVLP) - a referral platform and tissue pathway for personalised cancer vaccine trials. 

We’re especially proud of the praise from the trial organiser for engaging and getting involved so quickly.

Mr Alistair Myers, consultant colorectal surgeon at our Trust, who is the local principal investigator, and our Research and Development Team have been singled out by the Clinical Trials Unit at the University of Southampton for successfully gaining consent then referring a patient in the quickest time from our Trust being activated as a participant, a process which took less than a week.

The CVLP will allow patients with cancer in Hillingdon to participate at the earliest possible opportunity in cancer vaccine trials and help accelerate the development of those vaccines.

Eligible patients with colorectal cancer who are receiving treatment at Hillingdon Hospital are being identified. With their consent, they are referred for recruitment into a trial called BNT122-01.

Participants will have their tumour mutations studied and sequenced, which will be used to create a vaccine tailored to that patient. The aim is to develop a vaccine which will stimulate the immune system to recognise and destroy the cancer cells.

Picture: Mariam Nasseri, research nurse, and Alistair Myers, consultant, of the Hillingdon team